Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vitro testing of new anti-CD20 antibody formats in pediatric B-cell non-Hodgkin lymphoma
NL-OMON53135Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of rituximab in B-cell non-Hodgkin lymphoma (B-NHL) (3 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Effectiveness of new anti-CD20 monoclonals in eliminating malignant CD20-positive B cells and Superiority of IgA versus IgG in malignant B-cell elimination. Started Nov 2021; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NL-OMON53135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53135.